Promotional content developed and funded by Novartis Pharmaceuticals UK Ltd
for UK healthcare professionals only

Prescribing information Adverse event reporting information 

INGRAIN-MF
Incorporating genetics, risk and associated burden into MF management

MODULE 2: The influence of genetic factors in myelofibrosis

Introduction

Constitutive activation of the JAK-STAT signalling pathway is a hallmark of myeloproliferative neoplasms (MPNs), including myelofibrosis (MF).1 In addition to the common ‘driver’ mutations, a wide range of other non-driver mutations has been identified.1 Together, these mutations influence the prognosis for an individual, as well as how they respond to treatment.1-3 Accessing and understanding the molecular profile of patients with MF allows more accurate diagnosis, risk stratification and informed treatment decisions.1

In this module, you will learn about:

  • driver and non-driver mutations in MF
  • the importance of genetic information in diagnosis
  • how a patient’s molecular profile affects their prognosis
  • the potential offered by next-generation sequencing (NGS)

Multiple-choice questions (MCQs) to test your current knowledge

These MCQs will help you assess your current knowledge of this topic before you begin to work through the module. Your answers will be marked but will not count towards your final score. You will be asked the same MCQs at the end of the module. You will be able to download a learning certificate for your records upon completion.

G-CSF: granulocyte-colony stimulating factor

NGS: next-generation sequencing

Continue to section 1: Driver mutations in myelofibrosis 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370

References
  1. Loscocco G G, Guglielmelli P, Vannucchi A M. Impact of mutational profile on the management of myeloproliferative neoplasms: a short review of the emerging data. Onco Targets Ther 2020;13:12367-12382
  2. Mannina D, Gagelmann N et al. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation. Eur J Haematol 2019;103(6):552-557
  3. Patel K P, Newberry K J et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 2015;126(6):790-797